BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: CFA showed that imatinib treatment alone dramatically reduced primary CML progenitors without the BIM deletion polymorphism by approximately 80% but only reduced those with the BIM deletion polymorphism by 50% (compare Fig 4B to 4D).